Premium
Outcomes and endpoints in glaucoma
Author(s) -
Cordeiro M.F.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.01524
Subject(s) - glaucoma , medicine , clinical trial , neuroprotection , clinical endpoint , disease , ophthalmology , optometry , neuroscience , intensive care medicine , pathology , psychology
Summary Clinical trials in glaucoma have historically relied in IOP . However, the emergence of neuroprotection in glaucoma ghas lead to a need for new measures of trial success. Several potential outcomes exist including autoimmune and genetic biomarkers, brain and retina imaging, clinical signatures of RGC disease and structural and functional endpoints. These will be covered in this talk including DARC – detection of apoptosing cells.